euro adhoc: Intercell AG / Personnel / Intercell AG appoints Thomas Lingelbach

--------------------------------------------------------------------------------
Disclosure announcement transmitted by euro adhoc.
The issuer is responsible for the content of this announcement.
--------------------------------------------------------------------------------

03.08.2006

Intercell AG (VSE, "ICLL") today announced the recruitment of Thomas
Lingelbach as Chief Operating Officer of Intercell and Managing
Director of Intercell Biomedical Ltd. (Scotland), the operating site
for the commercial production of Intercells Japanese Encephalitis
Vaccine. Within his function beginning on October 1st, 2006, he will
play a pivotal role in establishing Intercell´s commercial
manufacturing as well as its further production and process
development.

He started his professional career in the pharma industry in 1989 at
Hoechst AG, Frankfurt (Germany). From 2001 till Chiron's acquisition
by Novartis in April 2006, he served as Vice President Industrial
Operations in Chiron Vaccines' Executive Committee as well as
Managing Director for Chiron-Behring GmbH & Co. KG in Germany. Most
recently he has been significantly involved in Novartis' Vaccines and
Diagnostics integration activities acting as General Manager and
Managing Director for its German Vaccines Operations.

Thomas Lingelbach successfully transformed Chiron Vaccines'
industrial operations into a globally integrated function with center
of excellence sites in Germany, Italy, the UK and India. He
implemented key processes for technology industrialization, supply
chain and industrial product management. In his capacity he played an
integral part in getting Fluvirin back on the market in 2005, when he
led the remediation efforts at the Liverpool site in close
collaboration with MHRA and FDA. Furthermore, he enabled the Marburg
site to become the first commercially viable flu cell culture
manufacturing facility.

"Thomas Lingelbach's profound experience, his leadership competences
and prominent position in the human vaccine field is another example
of Intercell's philosophy to build a top-class worldwide business
with outstanding staff", states Gerd Zettlmeissl, Intercell's Chief
Executive Officer.

About Intercell AG

Intercell AG is a biotechnology company focused on the research,
development, manufacturing and future commercialization of innovative
vaccines for the prevention and treatment of infectious diseases, for
which there exists a substantial unaddressed medical need. Intercell
develops antigens and immunizers (adjuvants), which are derived from
its proprietary technology platforms and has in-house GMP
manufacturing capability. Intercell has strategic partnerships with a
number of global pharmaceutical companies, including Novartis, Sanofi
Pasteur S.A., Merck & Co., Inc., SciGen Ltd., the Statens Serum
Institut and Kirin Brewery Co. Ltd. Intercell has a broad development
pipeline with a vaccine product candidate for Japanese Encephalitis
in Phase III clinical trials, where Novartis will be the strategic
partner for marketing and distribution, a vaccine product candidate
for Hepatitis C in Phase II, partnered vaccine candidates for
Tuberculosis and S. aureus, which are in Phase I, and more than five
other product candidates focused on infectious diseases in
pre-clinical development. Intercell is listed on the Vienna stock
exchange under the symbol "ICLL".

For picture download of Thomas Lingelbach or more information, please
visit the press section on www.intercell.com

end of announcement euro adhoc 03.08.2006 08:03:03
--------------------------------------------------------------------------------

ots Originaltext: Intercell AG
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:
Intercell AG
Mag. Katharina Wieser
Head of Corporate Communications
Tel. +43 1 20620-303
kwieser@intercell.com

Branche: Biotechnology
ISIN: AT0000612601
WKN: A0D8HW
Börsen: Wiener Börse AG / official market